Artemisinin-based combination therapy for ... - The Cochrane Library

More documents

Recommendations

Info

$Interventions for treating proximal humeral fractures in adults (Review)$

Analysis 18.1. Comparison 18 How does Dihydroartemisinin-piperaquine perform?, Outcome 1 Effectiveness: Total Failure (P. falciparum) PCR adjusted. Review: Artemisinin-based combination therapy for treating uncomplicated malaria Comparison: 18 How does Dihydroartemisinin-piperaquine perform? Outcome: 1 Effectiveness: Total Failure (P. falciparum) PCR adjusted Study or subgroup DHA-P Control Risk Ratio Weight Risk Ratio 1 Day 63: DHA-P vs Artesunate plus mefloquine n/N n/N M-H,Random,95% CI M-H,Random,95% CI Ashley 2003b THA 3/131 9/131 31.2 % 0.33 [ 0.09, 1.20 ] Janssens 2003 KHM 4/181 5/190 30.8 % 0.84 [ 0.23, 3.08 ] Ashley 2004 THA 3/292 7/137 29.6 % 0.20 [ 0.05, 0.77 ] Grande 2005 PER 4/211 0/224 8.4 % 9.55 [ 0.52, 176.35 ] Subtotal (95% CI) 815 682 100.0 % 0.57 [ 0.17, 1.83 ] Total events: 14 (DHA-P), 21 (Control) Heterogeneity: Tau 2 = 0.78; Chi 2 = 6.94, df = 3 (P = 0.07); I 2 =57% Test for overall effect: Z = 0.95 (P = 0.34) 2 Day 42: DHA-P vs Artemether-lumefantrine Ratcliff 2005 IDN 3/179 3/138 11.7 % 0.77 [ 0.16, 3.76 ] Kamya 2006 UGA 13/130 28/117 31.8 % 0.42 [ 0.23, 0.77 ] Karunajeewa 2007 PNG 12/77 5/74 21.3 % 2.31 [ 0.85, 6.23 ] Zongo 2007 BFA 4/163 7/128 17.0 % 0.45 [ 0.13, 1.50 ] Yeka 2007 UGA 4/190 10/141 18.2 % 0.30 [ 0.10, 0.93 ] Subtotal (95% CI) 739 598 100.0 % 0.62 [ 0.29, 1.30 ] Total events: 36 (DHA-P), 53 (Control) Heterogeneity: Tau 2 = 0.42; Chi 2 = 10.17, df = 4 (P = 0.04); I 2 =61% Test for overall effect: Z = 1.26 (P = 0.21) 3 Day 28: DHA-P vs Artesunate plus amodiaquine Karema 2004 RWA 10/236 16/222 78.2 % 0.59 [ 0.27, 1.27 ] Hasugian 2005 IDN 1/90 6/81 21.8 % 0.15 [ 0.02, 1.22 ] Subtotal (95% CI) 326 303 100.0 % 0.42 [ 0.13, 1.35 ] Total events: 11 (DHA-P), 22 (Control) Heterogeneity: Tau 2 = 0.31; Chi 2 = 1.47, df = 1 (P = 0.22); I 2 =32% Test for overall effect: Z = 1.46 (P = 0.15) 4 Day 42: DHA-P vs Artesunate plus sulfadoxine-pyrimethamine Karunajeewa 2007 PNG 12/77 17/84 100.0 % 0.77 [ 0.39, 1.51 ] Subtotal (95% CI) 77 84 100.0 % 0.77 [ 0.39, 1.51 ] Total events: 12 (DHA-P), 17 (Control) 0.005 0.1 1 10 200 Favours DHA-P Favours Control Artemisinin-based combination therapy for treating uncomplicated malaria (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. (Continued ...) 210
(... Continued) Study or subgroup DHA-P Control Risk Ratio Weight Risk Ratio Heterogeneity: not applicable Test for overall effect: Z = 0.76 (P = 0.45) 5 Day 28: DHA-P vs Amodiaquine plus sulfadoxine-pyrimethamine n/N n/N M-H,Random,95% CI M-H,Random,95% CI Karema 2004 RWA 10/236 38/227 63.8 % 0.25 [ 0.13, 0.50 ] Zongo 2007 BFA 4/172 7/167 36.2 % 0.55 [ 0.17, 1.86 ] Subtotal (95% CI) 408 394 100.0 % 0.32 [ 0.16, 0.64 ] Total events: 14 (DHA-P), 45 (Control) Heterogeneity: Tau 2 = 0.06; Chi 2 = 1.24, df = 1 (P = 0.27); I 2 =19% Test for overall effect: Z = 3.23 (P = 0.0012) 0.005 0.1 1 10 200 Favours DHA-P Favours Control Analysis 19.1. Comparison 19 How does Artesunate plus mefloquine perform?, Outcome 1 Effectiveness: Total Failure (P. falciparum) PCR adjusted. Review: Artemisinin-based combination therapy for treating uncomplicated malaria Comparison: 19 How does Artesunate plus mefloquine perform? Outcome: 1 Effectiveness: Total Failure (P. falciparum) PCR adjusted Study or subgroup ASMQ Control Risk Ratio Risk Ratio 1 Day 63: AS+MQ vs Dihydroartemisinin-piperaquine n/N n/N M-H,Random,95% CI M-H,Random,95% CI Ashley 2003b THA 9/131 3/131 3.00 [ 0.83, 10.83 ] Janssens 2003 KHM 5/190 4/181 1.19 [ 0.32, 4.36 ] Ashley 2004 THA 7/137 3/292 4.97 [ 1.31, 18.94 ] Grande 2005 PER 0/224 4/211 0.10 [ 0.01, 1.93 ] Subtotal (95% CI) 682 815 1.77 [ 0.55, 5.72 ] Total events: 21 (ASMQ), 14 (Control) Heterogeneity: Tau 2 = 0.78; Chi 2 = 6.94, df = 3 (P = 0.07); I 2 =57% Test for overall effect: Z = 0.95 (P = 0.34) 2 Day 42: AS+MQ vs Artemether-lumefantrine Hutagalung 2002 THA 9/212 3/201 2.84 [ 0.78, 10.36 ] Van den Broek 2003a BGD 0/105 3/102 0.14 [ 0.01, 2.65 ] Stohrer 2003 LAO 0/45 3/37 0.12 [ 0.01, 2.21 ] Artemisinin-based combination therapy for treating uncomplicated malaria (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. 0.005 0.1 1 10 200 Favours ASMQ Favours Control (Continued ...) 211
Page 1 and 2:
Artemisinin-based combination thera
Page 3 and 4:
Analysis 2.2. Comparison 2 Dihydroa
Page 5 and 6:
Analysis 10.5. Comparison 10 Arteme
Page 7 and 8:
[Intervention Review] Artemisinin-b
Page 9 and 10:
B A C K G R O U N D Malaria is a di
Page 11 and 12:
drugs and the treatment comparisons
Page 13 and 14:
this analysis into participants who
Page 15 and 16:
Figure 1. Methodological quality su
Page 17 and 18:
confidence intervals of the estimat
Page 19 and 20:
Anaemia Hasugian 2005 IDN found tha
Page 21 and 22:
Three trials report significantly m
Page 23 and 24:
or those treated for P. vivax at ba
Page 25 and 26:
Early vomiting Not reported. D I S
Page 27 and 28:
Figure 4. Olliaro-Vaillant plot. Da
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Figure 10. Olliaro-Vaillant plot. D
Page 35 and 36:
of findings tables’. For these ta
Page 37 and 38:
Huambo and Bie provinces, central A
Page 39 and 40:
References to studies excluded from
Page 41 and 42:
Adjuik 2004 Adjuik M, Babiker A, Ga
Page 43 and 44:
C H A R A C T E R I S T I C S O F S
Page 45 and 46:
Ashley 2003a THA (Continued) Outcom
Page 47 and 48:
Ashley 2003b THA (Continued) Alloca
Page 49 and 50:
Ashley 2005 THA (Continued) Exclusi
Page 51 and 52:
Bonnet 2004 GIN (Continued) Item Au
Page 53 and 54:
Bukirwa 2005 UGA Methods Trial desi
Page 55 and 56:
Djimde 2004 MLI (Continued) • AS
Page 57 and 58:
Dorsey 2006 UGA (Continued) Item Au
Page 59 and 60:
Fanello 2004 RWA Methods Trial desi
Page 61 and 62:
Faye 2003 SEN (Continued) Outcomes
Page 63 and 64:
Grande 2005 PER (Continued) Allocat
Page 65 and 66:
Guthmann 2004 AGO (Continued) All d
Page 67 and 68:
Hasugian 2005 IDN Methods Trial des
Page 69 and 70:
Hutagalung 2002 THA (Continued) 5.
Page 71 and 72:
Janssens 2003 KHM (Continued) Free
Page 73 and 74:
Karema 2004 RWA (Continued) Interve
Page 75 and 76:
Karunajeewa 2007 PNG (Continued) Ri
Page 77 and 78:
Kobbe 2007 GHA (Continued) Exclusio
Page 79 and 80:
Koram 2003 GHA (Continued) Adequate
Page 81 and 82:
Martensson 2003 TZA Methods Trial d
Page 83 and 84:
Mayxay 2003 LAO (Continued) 1. Feve
Page 85 and 86:
Menard 2006 MDG Methods Trial desig
Page 87 and 88:
Mens 2007 KEN (Continued) Risk of b
Page 89 and 90:
Mutabingwa 2004 TZA (Continued) •
Page 91 and 92:
Owusu-Agyei 2006 GHA (Continued) Fr
Page 93 and 94:
Sagara 2005b MLI (Continued) • 25
Page 95 and 96:
Smithuis 2004 MMR (Continued) Risk
Page 97 and 98:
Stohrer 2003 LAO Methods Trial desi
Page 99 and 100:
Swarthout 2004 ZAR (Continued) Note
Page 101 and 102:
Tran 2002 VNM Methods Trial design:
Page 103 and 104:
Van den Broek 2003a BGD (Continued)
Page 105 and 106:
Van Vugt 1998 THA Methods Trial des
Page 107 and 108:
Yeka 2004 UGA (Continued) Risk of b
Page 109 and 110:
Yeka 2007 UGA (Continued) Free of o
Page 111 and 112:
Zongo 2007 BFA (Continued) Novartis
Page 113 and 114:
(Continued) Fofana 2005 Conference
Page 115 and 116:
D A T A A N D A N A L Y S E S Compa
Page 117 and 118:
2.2 Asia 1 317 Risk Ratio (M-H, Fix
Page 119 and 120:
Comparison 5. Dihydroartemisinin-pi
Page 121 and 122:
Comparison 8. Artesunate plus meflo
Page 123 and 124:
Comparison 10. Artemether-lumefantr
Page 125 and 126:
Comparison 12. Artesunate plus amod
Page 127 and 128:
5.2 DHA-P 3 doses 3 1116 Risk Ratio
Page 129 and 130:
Comparison 21. How does Artesunate
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
(... Continued) Study or subgroup D
Page 139 and 140:
Analysis 1.12. Comparison 1 Dihydro
Page 141 and 142:
(... Continued) Study or subgroup D
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
(... Continued) Study or subgroup A
Page 165 and 166: Analysis 6.6. Comparison 6 Artesuna
Page 173 and 174: Analysis 9.2. Comparison 9 Artemeth
Page 175 and 176: (... Continued) Study or subgroup A
Page 177 and 178: Analysis 9.8. Comparison 9 Artemeth
Page 183 and 184: Analysis 10.2. Comparison 10 Arteme
Page 197 and 198: Analysis 12.2. Comparison 12 Artesu
Page 207 and 208: Analysis 14.2. Comparison 14 Dihydr
Page 215: Analysis 17.1. Comparison 17 Artesu
Page 219 and 220: Analysis 20.1. Comparison 20 How do
Page 221 and 222: Analysis 21.1. Comparison 21 How do
Page 223 and 224: (Continued) 2. How does artesunate
Page 225 and 226: (Continued) Sensitivity analysis 1
Page 227 and 228: (Continued) Smithuis 2004 MMR (652
Page 229 and 230: Dihydroartemisinin-piperaquine vs A
Page 231 and 232: (Continued) Mayxay 2003 LAO (220 pa
Page 233 and 234: Artesunate plus mefloquine vs Amodi
Page 235 and 236: (Continued) Faye 2003 SEN (509 part
Page 237 and 238: Artemether-lumefantrine vs Artesuna
Page 239 and 240: (Continued) Zongo 2005 BFA (521 par
Page 241 and 242: (Continued) Faye 2003 SEN (521 part
Page 243 and 244: PCR = polymerase chain reaction PCV
Page 245 and 246: (Continued) Proportion with anaemia
Page 247 and 248: (Continued) Vivax efficacy: P. viva
Page 249 and 250: (Continued) Efficacy: Total Failure
Page 251 and 252: (Continued) Outcomes Illustrative c
Page 255 and 256: (Continued) GRADE Working Group gra
Page 257 and 258: Footnotes 1 Data were also availabl
Page 259 and 260: 8 Very serious imprecision: There w
Page 263 and 264: (Continued) justed Vivax efficacy:
Page 265 and 266: (Continued) Harms: Serious adverse
Page 267 and 268:
(Continued) Harms: Early vomiting -
Page 269 and 270:
1 Dorsey 2006 UGA; Faye 2003 SEN; K
show all

Artemisinin-based combination therapy for ... - The Cochrane Library

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?